3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Genitourinary
1
Conditions
Multiple Myeloma
52
Recurrence
5
Neoplasms, Plasma Cell
3
Immunoglobulin Light-chain Amyloidosis
3
Amyloidosis
2
Renal Insufficiency
1
Plasmablastic Lymphoma
1
Kidney Failure, Chronic
1
Interventions
Dexamethasone
13
Bortezomib
8
Cyclophosphamide
6
Lenalidomide
4
pomalidomide
3
isatuximab
3
Kidney Transplantation
3
Calcium Dobesilate
3
glucarpidase
2
Thalidomide
2
Paclitaxel
2
Gemcitabine
2
Carboplatin
2
Bendamustine Hydrochloride
2
Azacitidine
2
vinflunine
1
veliparib
1
trifluridine tipiracil drug combination
1
trebananib
1
safinamide
1
sacubitril and valsartan sodium hydrate drug combination
1
rubitecan
1
ripretinib
1
regorafenib
1
pevonedistat
1
pembrolizumab
1
osimertinib
1
mirabegron
1
melflufen
1
gamma-Glutamyl Hydrolase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Renal Insufficiency
×
belantamab mafodotin
×
Clear all
NCT04398745
2025-05-23
DREAMM12
GlaxoSmithKline
Phase 1
Active not recruiting
36 enrolled